Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/8992
Título
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
Autor(es)
Rondy, Marc | Kissling, Esther | Emborg, Hanne-Dorthe | Gherasim, Alin Manuel ISCIII | Pebody, Richard | Trebbien, Ramona | Pozo Sanchez, Francisco ISCIII | Larrauri, Amparo ISCIII | McMenamin, Jim | Valenciano, Marta | I-MOVE/I-MOVE+ group | Delgado-Sanz, Concepcion ISCIII | Oliva Dominguez, Jesus Angel ISCIII | Casas Flecha, Inmaculada ISCIII
Fecha de publicación
2018
Cita
Euro Surveill. 2018 Mar;23(9):18-00086.
Idioma
Inglés
Tipo de documento
journal article
Resumen
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Palabras clave
Europe | Case control study | Influenza | Influenza vaccination | Influenza vaccine effectiveness | Multicentre study
MESH
Adolescent | Adult | Aged | Child | Child, Preschool | Europe | European Union | Female | Humans | Infant | Infant, Newborn | Influenza A Virus, H1N1 Subtype | Influenza A Virus, H3N2 Subtype | Influenza B virus | Influenza Vaccines | Influenza, Human | Male | Middle Aged | Pandemics | Treatment Outcome | Vaccination | Seasons
Versión en línea
DOI
Aparece en las colecciones